Pulmonary hypertension (PH) is a complex, progressive condition characterized by elevated pulmonary artery pressure and pulmonary vascular resistance. This article provides a comprehensive overview of the fundamental aspects of PH, including its pathophysiology, diagnosis, and management strategies.
PH is primarily a disorder of the pulmonary vasculature. It is characterized by vasoconstriction, vascular remodeling, and in situ thrombosis. These changes lead to increased pulmonary vascular resistance and subsequently elevated pulmonary artery pressure. The disease is classified into five groups based on the underlying cause, each with distinct pathophysiological mechanisms.
Diagnosis of PH involves a combination of clinical evaluation, echocardiography, and right heart catheterization. Echocardiography is a non-invasive tool used for initial assessment, while right heart catheterization is the gold standard for confirming the diagnosis. Additional tests such as pulmonary function tests, chest radiographs, and CT scans may be required to identify the underlying cause.
Treatment of PH is multifaceted and depends on the underlying cause. General measures include lifestyle modifications, oxygen therapy, and anticoagulation. Specific therapies target the three main pathways involved in the pathogenesis: the nitric oxide, endothelin, and prostacyclin pathways. Lung transplantation may be considered in severe, refractory cases.
PH is a complex disease with a multifactorial pathogenesis and diverse clinical manifestations. Understanding its fundamentals is crucial for its early diagnosis and effective management. As physicians, maintaining a high index of suspicion and adopting a systematic approach to diagnosis can significantly improve patient outcomes. Continuous research in this field is essential to develop more effective therapeutic strategies.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation